- Medical - Instruments & Supplies
- Healthcare
-
4.88
EPS
-
49.56
P/E
-
69.9B
MARKET CAP
-
1.55%
DIV YIELD
Company Overview
ONE BECTON DR,FRANKLIN LAKES NJ 07417-1880,2018476800
CEO
Mr. Thomas E. Polen Jr.
Employess
70000
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Website
https://www.bd.com
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Next Earnings Date
Nov. 14, 2024
Ex Dividends date
Sep. 30, 2024
Dividend Date
Sept. 9, 2024
YTD Performance
-1.45%
Fiscal Year End
09-30
IPO Date
1973-02-21
Growth Rates
(avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
---|---|---|---|---|
Sales/Revenue | 9.17% | 3.92% | 4.21% | 2.66% |
EPS | -2.84% | 32.87% | 21.81% | -16.19% |
Equity | 17.73% | 4.21% | 2.76% | 1.96% |
Cash | -2.85% | 4.43% | -20.56% | 40.76% |
Return On Capital (ROIC) | 5.56% | 4.75% | 5.35% | 4.66% |
Debt
year (millions) | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Short Term Debt | 1,140 | 2,180 | 500 | 707 | 1,310 |
Long Term Debt | 14,700 | 13,900 | 17,100 | 17,200 | 18,100 |
LT Finance Leases | 1,020 | 877 | 1,230 | 1,440 | 1,270 |
Shares Outstanding | 286 | 285 | 289 | 279 | 270 |
Market Cap | 74,000 | 63,500 | 69,300 | 63,300 | 66,600 |
Price
News
BD (BDX) Q3 Earnings Surpass Estimates, Margins Expand
2 monthsBD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.
zacks.comBecton, Dickinson and Company (BDX) Q3 2024 Earnings Call Transcript
2 monthsBecton, Dickinson and Company (NYSE:BDX ) Q3 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer & Head of Investor Relations Tom Polen - Chairman, Chief Executive Officer & President Chris DelOrefice - Executive Vice President & Chief Financial Officer Mike Garrison - President of the Medical Segment Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America David Roman - Goldman Sachs Patrick Wood - Morgan Stanley Larry Biegelsen - Wells Fargo Rick Wise - Stifel Vijay Kumar - Evercore ISI Operator Hello and welcome to BD's Third Quarter Fiscal 2024 Earnings Conference Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website at investors.bd.com or by phone at 800-839-2385 for domestic calls and area code +1 402-220-7203 for international calls.
seekingalpha.comCompared to Estimates, Becton Dickinson (BDX) Q3 Earnings: A Look at Key Metrics
2 monthsAlthough the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.comBecton Dickinson (BDX) Q3 Earnings Beat Estimates
2 monthsBecton Dickinson (BDX) came out with quarterly earnings of $3.50 per share, beating the Zacks Consensus Estimate of $3.31 per share. This compares to earnings of $2.96 per share a year ago.
zacks.comBecton Dickinson tops profit estimates on demand for drug-delivery devices
2 monthsBecton Dickinson reported a better-than-expected third-quarter profit on Thursday, helped by strong demand for its drug-delivery devices.
reuters.comBD Reports Third Quarter Fiscal 2024 Financial Results
2 monthsStrong Margin Execution Drives Performance in Quarter Revenue of $5.0 billion as reported, adjusted revenue of $5.1 billion, driven by strong organic revenue growth GAAP and adjusted diluted EPS of $1.68 and $3.50 grew 23.5% and 18.2%, respectively Year-to-date Cash from Continuing Operations grew 60% to $2.7 billion and Free Cash Flow grew over 100% to $2.2 billion, increasing $1.0 billion and $1.2 billion since the prior year, respectively The company updated its fiscal 2024 GAAP revenue growth guidance to approximately 3.7%, and its organic revenue growth guidance to 5.0% to 5.25% The company increased its fiscal 2024 adjusted diluted EPS guidance by 5 cents at the midpoint to $13.05 to $13.15 1 FRANKLIN LAKES, N.J. , Aug. 1, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its third quarter of fiscal 2024, which ended June 30, 2024.
prnewswire.comSustained Product Demand Likely to Aid BD's (BDX) Q3 Earnings
2 monthsContinued solid uptake of BD's (BDX) products is expected to have driven fiscal third-quarter revenues.
zacks.comCountdown to Becton Dickinson (BDX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
2 monthsLooking beyond Wall Street's top -and-bottom-line estimate forecasts for Becton Dickinson (BDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
zacks.comBD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases
2 monthsCollaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care FRANKLIN LAKES, N.J. and SECAUCUS, N.J.
prnewswire.comBD Board Declares Dividend
2 monthsFRANKLIN LAKES, N.J. , July 23, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024.
prnewswire.comWhat Makes Becton Dickinson (BDX) a New Buy Stock
2 monthsBecton Dickinson (BDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.comBDX vs. MMSI: Which Stock Should Value Investors Buy Now?
2 monthsInvestors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now?
zacks.com